SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lincoln Pharmaceuticals informs about outcome of board meeting

10 Nov 2022 Evaluate
Lincoln Pharmaceuticals has informed that pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), the Board of Directors of the Company at its meeting held today have considered/ approved/ recommended the followings: The un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30, 2022 along with the limited review report from auditors thereon. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of un-audited consolidated financial results for the quarter and half year ended on September 30, 2022. The un-audited financial results (standalone and consolidated) will be available at Company's website at www.lincolnpharma.com. Further, it has enclosed financial highlights for the aforesaid quarter. The appointment of Trusha Shah (Membership no. AS9416) as Company Secretary and Compliance Officer of the Company with effective from 10th November, 2022. A brief profile of Trusha Shah and the disclosure as required under Regulation 30(6) read with Schedule III Part A Para A (1) of the Listing Regulations and the SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September 2015 is attached as Annexure A. Meeting of the Board of Directors commenced at 9.45 AM and concluded at 11.15 AM.

The above information is a part of company’s filings submitted to BSE.

Lincoln Pharma Share Price

640.05 -5.35 (-0.83%)
04-May-2026 09:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1829.55
Dr. Reddys Lab 1298.00
Cipla 1321.50
Zydus Lifesciences 897.75
Lupin 2324.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×